IP Library Granted Patent US 8,029,789
Granted Patent B2
US 8,029,789 · App. 10/535,312 · Granted Oct 4, 2011

Method for the mass production of immunoglobulin constant region

Assignee: Hanmi Holdings Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,029,789
App. No.
10/535,312
Granted
Oct 4, 2011
Kind
B2
Abstract

Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli -derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.

Claims (16)

1. A method of producing an immunoglobulin constant region, comprising:

transforming E. coli with a recombinant expression vector including a nucleotide sequence encoding an E. coli signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, without a variable region;

culturing a resulting transformant in a medium to overexpress the immunoglobulin constant region in the cytoplasm of the transformant; and

isolating the immunoglobulin constant region expressed by the transformant,

wherein the signal sequence is a heat-stable enterotoxin II signal sequence, and wherein the immunoglobulin constant region is expressed in the cytoplasm in a water soluble form and is not secreted into the medium or the periplasmic space, and wherein the transformant is selected from the group consisting of E. coli BL21/pSTIIGICH1 3 (HM10935; Deposit No. KCCM-10600), BL21/pSTIIdCG1Fc (HM10927; Deposit No. KCCM-10588), BL21/pSTIIdCG1SFc (HM10928; Deposit No. KCCM-10589), BL21/pSTIIdCG1SFFc (HM10929; Deposit No. KCCM-10594), BL21/pSTIIG1Mo (HM10930; Deposit No. KCCM10595), BL21/pSTIIdCG4Fc (HM10932; Deposit No. KCCM-10597), BL21/pSTIIG4CH1 3 (HM10931; Deposit No. KCCM-10596), BL21/pSTIIG4Mo (HM10933; Deposit No. KCCM-10598), and BL21/pSTIIG4H K (HM10934; Deposit No. KCCM-10599).

2. The method according to claim 1 , wherein the immunoglobulin constant region is selected from the group consisting of constant regions from IgG, IgA, IgM, IgE, and IgD.

3. The method according to claim 2 , wherein the IgG is selected from the group consisting of constant regions from IgG1, IgG2, IgG3, and IgG4.

4. The method according to claim 3 , wherein the immunoglobulin constant region is an IgG4 constant region.

5. The method according to claim 4 , wherein the immunoglobulin constant region is a human aglycosylated IgG4 constant region.

6. The method according to claim 1 , wherein the immunoglobulin constant region lacks all or a portion of a hinge region.

7. The method according to claim 1 , wherein the recombinant expression vector comprises a nucleotide sequence encoding a heavy chain constant 1 region or a nucleotide sequence encoding a light chain constant region.

8. The method according to claim 1 , wherein the immunoglobulin constant region has an amino acid sequence represented by SEQ ID NO. 21, 22, 23, 24, 25, 27, 29, 30, 34 or 35.

9. The method according to claim 1 , wherein the heat-stable enterotoxin II signal peptide has an amino acid sequence represented by SEQ ID NO. 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46.

10. The method according to claim 1 , wherein the recombinant expression vector comprises the signal sequence, and a nucleotide sequence encoding an immunoglobulin constant region of SEQ ID NOs: 21-25, 27, 29, 30, 34, or 35.

11. An immunoglobulin constant region prepared by the method of claim 1 .

12. The method according to claim 1 , wherein the immunoglobulin constant region lacks all or a portion of a hinge region.

Assignments (3)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2011
From: HANMI PHARMACEUTICAL CO., LTD.
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 025588/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2006
From: JUNG, SUNG YOUB; KIM, JIN SUN; PARK, YOUNG JIN; CHOI, KI-DOO; KWON, SE CHANG; LEE, GWAN SUN
To: HANMI PHARM. IND. CO., LTD.
Reel/Frame 017725/0669 →
Priority Claims (1)
KR 10-2003-0080299 · Nov 13, 2003 · national
Continuity (1)
Related Publication 20060276633A1 · Dec 7, 2006